CTOs on the Move

IntegenX

www.integenx.com

 
IntegenX is a Pleasanton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.integenx.com
  • 5720 Stoneridge Dr Ste 300
    Pleasanton, CA USA 94588
  • Phone: 925.701.3400

Executives

Name Title Contact Details

Similar Companies

Oragenics

Oragenics is a publicly-traded biopharmaceutical company with a pipeline of unique proprietary technologies.

Reneo Pharmaceuticals

Reneo is a clinical stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases. Many of these diseases are associated with deficits in cellular metabolism and energy production. Our goal is to improve daily function and quality of life of patients suffering from these diseases, most specifically, by improving how their mitochondria work, preserving muscle function and preventing muscle injury, weakness and wasting.

OmniActive Health Technologies

OmniActive was born from Kancor Ingredients, an ingredient supplier rooted in the food and flavoring industry. Kancor has decades of experience extracting pure, quality ingredients from whole foods. With a history in extraction of natural products dating back to 1969, we at OmniActive are well versed in the technologies and processes necessary to provide specialized ingredients to the supplements space, as well as food and beverage companies. Kancor and OmniActive were both founded by the Mariwala family, with a long heritage in the spice industry. Patriarch Kanji Moorarji began trading in spices in 1857, an interest that continues to the present day. This history is reflected in the strength of our supply chain and raw material sourcing.

biozeen

biozeen is a Allentown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Encodia

Encodia is developing an innovative Next-Gen digital proteomics platform to enable democratized protein sequencing. Our goal is to make protein sequencing easy and ubiquitous by using a novel reverse-translation technology that turns peptide sequences into DNA. The DNA can be read by an NGS DNA sequencer, providing a path to breakthrough proteomics research at a scale that is not practical or cost-effective using current technologies.